BrainStorm Hosting Conference Call to Update Shareholders on Important Developments

BrainStorm Hosting Conference Call to Update Shareholders on Important 
NEW YORK, NY and PETAH TIKVA, ISRAEL -- (Marketwired) -- 04/22/14 -- 
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of
adult stem cell technologies for neurodegenerative diseases,
announced today that it will hold a conference call on Monday, April
28, 2014 at 8:45 a.m. Eastern Daylight Time (EDT), 15:45 Israel
Daylight Time (IDT).  Mr. Chaim Lebovits, BrainStorm's President and
Principal Executive Officer, will provide an update to shareholders
and discuss important company developments. 
The call will be conducted in English. Callers may participate in the
conference call by dialing: 
USA: 1-888-407-2553 
 Canada: 1-866-485-2399
 Israel: 03-918-0644 
International: +972-3-918-0644 
A recording of the conference call will be posted by Tuesday, April
29, 2014 on the company's website: 
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at  
Safe Harbor Statement
 Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements.  
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)
Mr. Chaim Lebovits
Phone: +972-3-9236384 
Press spacebar to pause and continue. Press esc to stop.